Module 1: Test to Treat – Interpreting HER2 Tissue and ctDNA Reports
Enhance your practice in managing HER2-mutant NSCLC. This course offers expert insights on interpreting HER2 tissue and ctDNA biopsy reports, empowering oncology clinicians to streamline biomarker testing and coordinate evidence-based treatment plans for their patients.
- Price
- Free
- Accredited provider:
- i3 Health Joint Providership
- Learning platform:
- IQ Apparatus
- Release date
- June 1, 2026
- Expires
- May 31, 2027